Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 362-369

  Messerschmidt, Sylvia K E ^a   Kolbe, Anke ^a   Müller, Dafne ^a   Knoll, Michael ^a   Pleiss, Jürgen ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYSTEINE; IMMUNOLIPOSOME; SEPRASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY COMBINING SITE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONJUGATE; CONJUGATION; GENETIC ENGINEERING; NONHUMAN; PROTEIN TARGETING; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

EID: 38949108975     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700349k     Document Type: Article

References (37)

1. Allen, T. M., and Cullis, P. R. (2004) Drug delivery systems: entering the mainstream. Science 303, 1818-1822.
2. Mastrobattista, E., Koning, G. A., and Storm, G. (1999) Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Delivery Rev. 40, 103-127.
3. Philipps, N. C., and Dahman, J. (1995) Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. 45, 149-152.
4. Bendas, G., Rothe, U., Scherphof, G. L., and Kamps, J. A. A. M. (2003) The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stablized immunoliposomes. Biochim. Biophys. Acta 1609, 63-70.
5. Koning, G. A., Morselt, H. W. M., Gorter, A., Allen, T. M., Zalipsky, S., Scherphof, G. L., and Kamps, J. A. A. M. (2003) Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm. Res. 20, 1249-1257.
6. Kontermann, R. E. (2006) Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8, 39-45.
7. Sapra, P., Moase, E. H., Ma, J., and Allen, T. M. (2004) Improved therapeutic responses in a xenograft model of human B lmyphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments. Clin. Cancer Res. 10, 1100-1111.
8. Kim, S. J., Park, Y., and Hong, H. J. (2005) Antibody engineering for the development of therapeutic antibodies. Mol. Cells 20, 17-29.
9. Marty, C., Scheidegger, P., Ballmer-Hofer, K., Klemenz, R., and Schwendener, R. A. (2001) Production of functionalized single-chain Fv antibody fragments to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expression Purif. 21, 156-164.
10. Völkel, T., Hölig, P., Merdan, T., Müller, R., and Kontermann, R. E. (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed agaisnt human endoglin (CD105). Biochim. Biophys. Acta 1663, 158-166.
11. Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., and Benz, C. C. (2001) Tumor targeting using anti-HER2 immunoliposomes. J. Controlled Release 74, 95-113.
12. Nataranja, A., Xiong, C.-Y., Albrecht, H., DeNardo, G. L., and DeNardo, S. J. (2005) Characterization of site-specific scFv PEGylation for tumor-targeting pharmaceuticals. Bioconjugate Chem. 16, 113-121.
13. Krimner, E. M., Hepp, J., Hoffmann, P., Bruckmaier, S., Petersen, L., Petsch, S., Parr, L., Schuster, I., Mangold, S., Lorenczewski, G., Lutterbüse, P., Buziol, S., Hochheim, I., Volkland, J., Molhoj, M., Sriskandarajah, M., Strasser, M., Itin, C., Wolf, A., Basu, A., Yang, K., Filupa, D., Sorensen, P., Kufer, P., Baeuerle, P., and Raum, T. (2006) A highly stable polyenthylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng., Des. Sel. 19, 461-470.
14. Shen, Z., Stryker, G. A., Mernaugh, R. L., Yu, L., Yan, H., and Zeng, X. (2005) Single-chain fragment variable antibody piezoimmunosensors. Anal. Chem. 77, 797-805.
15. Backmann, N., Zahnd, C., Huber, F., Bietsch, A., Plückthun, A., Lang, H.-P., Güntheroldt, H.-J., Hegner, M., and Gerber, C. (2005) A label-free immunosensor array using single-chain antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 102, 14587-14592.
16. Ackerson, C. J., Jadzinsky, P. D., Jensen, G. J., and Romberg, R. D. (2006) Rigid, specific, and discrete gold nanoparticle/antibody conjugates. J. Am. Chem. Soc. 128, 2635-2640.
17. 2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8, 301-314.
18. Nielsen, U. B., Kirpotin, D. B., Pickering, E. M., Hong, K., Park, J. W., Shalaby, M. R., Shao, Y., Benz, C. C., and Marks, J. D. (2002) Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591, 109-108.
19. Albrecht, H., Burke, P. A., Natarajan, A., Xiong, C. Y., Kalicinsky, M., DeNardo, G. L., and DeNardo, S. J. (2004) Production of soluble scFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric scFvs on demand. Bioconjugate Chem. 15, 16-26.
20. Rubio Demirovic, A., Marty, C., Console, S., Zeisberger, S. M., Ruch, C., Jaussi, R., Schwendener, R. A., and Ballmer-Hofer, K. (2005) Targeting human cancer cells with VEGF receptor-2-directed liposomes. Oncol. Rep. 13, 319-324.
21. Albrecht, H., DeNardo, G. L., and DeNardo, S. J. (2006) Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J. Immunol. Methods 310, 100-116.
22. Baum, P., Müller, D., Rüger, R., and Kontermann, R. E. (2007) Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J. Drug Target. 15, 399-406.
23. Rüger, R., Müller, D., Fahr, A., and Kontermann, R. E. (2005) Generation of immunoliposomes using recombinant single-chain Fv fragment bound to Ni-NTA-liposomes. J. Drug Target. 13, 399-406.
24. Nellis (2005) Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Prog. 21, 205-220.
25. Whitelegg, N. R. J., and Rees, A. R. (2000) WAM - an improved algorithm for modelling antibodies on the Web. Protein Eng. 13, 819-824.
26. Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815.
27. Sippl, M. J. (1993) Recognition of errors in three-dimensional structures of proteins. Proteins 17, 355-362.
28. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291.
29. Morris, A. L., MacArthur, M. W., Hutchinson, E. G., and Thornton, J. M. (1992) Stereochemical quality of protein structure coordinates. Proteins 12, 345-364.
30. Ishida, T., Iden, D. L., and Allen, T. M. (1999) A combinatorial approach to producing sterically stabilized (stealth) immunoliposomal drugs. FEBS Lett. 460, 129-133.
31. Allen, T. M., Sapra, P., and Moase, E. (2002) Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell. Mol. Biol. Lett. 7, 889-894.
32. Schmiedl., A., Breitling, F., Winter, C. H., Queitsch, I., and Dübel, S. (2000) Effects of unpaired cyteines on yield, solubility and activity of different recombinant antibody constructs expressed in E. coli. J. Immunol. Methods 242, 101-114.
33. Mamot, C., Drummond, D. C., Greiser, U., Hong, K., Kirpotin, D. B., Marks, J. D., and Park, J. W. (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63, 3154-3161.
34. Cheng, W. W. K., Das, D., Suresh, M., and Allen, T. M. (2007) Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim. Biophys. Acta 1768, 21-29.
35. Gosk, S., Gottstein, C., and Bendas, G. (2005) Targeting of immunoliposomes to endothelial cells expressing VCAM: a future strategy in cancer therapy. Int. J. Clin. Pharmacol. Ther. 43, 581-582.
36. Hu, H., Chen, D., Liu, Y., Deng, Y., Yang, S., Qiao, M., Zhao, J., and Zhao, X. (2006) Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide- stabilized Fv fragment on tumor cells. J. Pharm. Sci. 95, 192-199.
37. Terpe, K. (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 60, 523-533.